Outcome of High-Risk and Refractory AML/MDS Patients Receiving a FLAMSA Sequential Chemotherapy Regimen Followed by Reduced-Intensity Conditioning (RIC) and Allogeneic Hematopoeitic Stem Cell Transplantation (allo-HSCT)
Marie Y. Detrait(Hôpital Civil de Charleroi), Mauricette Michallet(Université Claude Bernard Lyon 1), Mohamad Mohty(Sorbonne Université), Giovanna Cannas(Hôpital Edouard Herriot), Nathalie Tedone(Hospices Civils de Lyon), Patrice Chevallier(Hotel Dieu Hospital), Stéphane Morisset(Lyon 1 Université), Fiorenza Barraco(Hôpital Lyon Sud), Youcef Chelghoum(Hôpital Edouard Herriot), Jihane Fattoum(Lyon 1 Université), Xavier Thomas(Hôpital Lyon Sud), Franck E. Nicolini(Université Claude Bernard Lyon 1), Mohamad Sobh(Ottawa Hospital), Jacques Delaunay(Hôtel-Dieu de Paris), Sophie Ducastelle(Hôpital Lyon Sud), Hélène Labussière(Hôpital Lyon Sud), Thierry Guillaume(Centre National de la Recherche Scientifique)
Cited by 5
Related Papers
Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study
|The Lancet|2012|1k
Ruxolitinib for Glucocorticoid-Refractory Acute Graft-versus-Host Disease
|New England Journal of Medicine|2020|859
Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials
|The Lancet Oncology|2014|703
Should Adolescents With Acute Lymphoblastic Leukemia Be Treated as Old Children or Young Adults? Comparison of the French FRALLE-93 and LALA-94 Trials
|Journal of Clinical Oncology|2003|606
Pediatric-Inspired Therapy in Adults With Philadelphia Chromosome–Negative Acute Lymphoblastic Leukemia: The GRAALL-2003 Study
|Journal of Clinical Oncology|2009|562